X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs AUROBINDO PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA AUROBINDO PHARMA SUN PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 32.5 19.6 166.0% View Chart
P/BV x 2.5 3.7 68.6% View Chart
Dividend Yield % 0.5 0.3 147.0%  

Financials

 SUN PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
AUROBINDO PHARMA
Mar-18
SUN PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs701809 86.6%   
Low Rs433504 86.0%   
Sales per share (Unadj.) Rs110.4281.1 39.3%  
Earnings per share (Unadj.) Rs11.041.4 26.5%  
Cash flow per share (Unadj.) Rs17.250.9 33.9%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.40.4 92.7%  
Book value per share (Unadj.) Rs158.8199.4 79.7%  
Shares outstanding (eoy) m2,399.26585.88 409.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.3 219.8%   
Avg P/E ratio x51.615.9 325.3%  
P/CF ratio (eoy) x32.912.9 255.0%  
Price / Book Value ratio x3.63.3 108.4%  
Dividend payout %18.26.0 301.4%   
Avg Mkt Cap Rs m1,360,021384,630 353.6%   
No. of employees `00017.817.3 102.6%   
Total wages/salary Rs m53,67121,308 251.9%   
Avg. sales/employee Rs Th14,890.99,500.7 156.7%   
Avg. wages/employee Rs Th3,017.11,229.4 245.4%   
Avg. net profit/employee Rs Th1,480.61,397.9 105.9%   
INCOME DATA
Net Sales Rs m264,895164,666 160.9%  
Other income Rs m8,3881,020 822.5%   
Total revenues Rs m273,282165,686 164.9%   
Gross profit Rs m56,08137,718 148.7%  
Depreciation Rs m14,9985,580 268.8%   
Interest Rs m5,176777 665.9%   
Profit before tax Rs m44,29532,380 136.8%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4528,183 103.3%   
Profit after tax Rs m26,33824,229 108.7%  
Gross profit margin %21.222.9 92.4%  
Effective tax rate %19.125.3 75.5%   
Net profit margin %9.914.7 67.6%  
BALANCE SHEET DATA
Current assets Rs m316,359121,878 259.6%   
Current liabilities Rs m198,64386,806 228.8%   
Net working cap to sales %44.421.3 208.6%  
Current ratio x1.61.4 113.4%  
Inventory Days Days95130 73.0%  
Debtors Days Days10868 157.5%  
Net fixed assets Rs m213,17881,037 263.1%   
Share capital Rs m2,399586 409.5%   
"Free" reserves Rs m378,606116,218 325.8%   
Net worth Rs m381,006116,804 326.2%   
Long term debt Rs m17,7214,512 392.8%   
Total assets Rs m643,028211,052 304.7%  
Interest coverage x9.642.7 22.4%   
Debt to equity ratio x00 120.4%  
Sales to assets ratio x0.40.8 52.8%   
Return on assets %4.911.8 41.4%  
Return on equity %6.920.7 33.3%  
Return on capital %10.027.4 36.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81680,727 50.6%   
Fx outflow Rs m30,14334,700 86.9%   
Net fx Rs m10,67346,027 23.2%   
CASH FLOW
From Operations Rs m39,07219,548 199.9%  
From Investments Rs m-33,708-19,570 172.2%  
From Financial Activity Rs m-15,3938,642 -178.1%  
Net Cashflow Rs m-7,3598,922 -82.5%  

Share Holding

Indian Promoters % 63.7 54.1 117.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 8.0 64.5%  
FIIs % 23.0 27.7 83.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.2 81.4%  
Shareholders   133,026 69,601 191.1%  
Pledged promoter(s) holding % 0.5 8.6 6.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  IPCA LABS  CADILA HEALTHCARE  VENUS REMEDIES  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Down Over 550 Points(12:30 pm)

Share markets in India are presently trading on a negative note. All sectoral indices are trading in red with stocks in the realty sector, banking sector and capital goods sector.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Dec 10, 2018 03:35 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - TORRENT PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS